[{"id":"bb2676c0-4169-4f0b-8560-87eaebe4bee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408298","created_at":"2024-05-10T20:31:50.268Z","updated_at":"2024-07-02T16:35:04.490Z","phase":"Phase 1","brief_title":"HCQ in Resectable Localized Prostate Cancer","source_id_and_acronym":"NCT06408298","lead_sponsor":"Lionel.D.Lewis, MD","biomarkers":" BNIP3","pipe":"","alterations":" ","tags":["BNIP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-10"},{"id":"b8db270b-31ec-42b3-ae0d-efec0f07af53","acronym":"CLEVER","url":"https://clinicaltrials.gov/study/NCT03032406","created_at":"2021-01-18T14:55:32.607Z","updated_at":"2024-07-02T16:35:15.139Z","phase":"Phase 2","brief_title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","source_id_and_acronym":"NCT03032406 - CLEVER","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER • ALK • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-03-12"},{"id":"5e59385c-b0a6-4594-9da3-ea1896923dc1","acronym":"NТО-RAS","url":"https://clinicaltrials.gov/study/NCT06229340","created_at":"2024-01-29T17:21:16.419Z","updated_at":"2024-07-02T16:35:21.987Z","phase":"Phase 2","brief_title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","source_id_and_acronym":"NCT06229340 - NТО-RAS","lead_sponsor":"N.N. Petrov National Medical Research Center of Oncology","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • hydroxychloroquine • leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-01-29"},{"id":"88a56803-e53e-402f-8615-d502f691f9f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04682665","created_at":"2021-01-19T20:46:58.736Z","updated_at":"2024-07-02T16:35:27.981Z","phase":"","brief_title":"Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases","source_id_and_acronym":"NCT04682665","lead_sponsor":"University of Leeds","biomarkers":" PD-1 • CTLA4 • TIGIT • CCL2","pipe":"","alterations":" ","tags":["PD-1 • CTLA4 • TIGIT • CCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icosapent ethyl"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 09/16/2021","start_date":" 09/16/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-11-28"},{"id":"a9582e3e-99d1-4d84-a6a1-43c23c55626e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05647330","created_at":"2022-12-12T15:00:26.571Z","updated_at":"2024-07-02T16:35:59.264Z","phase":"Phase 2","brief_title":"Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05647330","lead_sponsor":"Henan Cancer Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation • EGFR negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • hydroxychloroquine • chloroquine phosphate"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-12-12"},{"id":"aae7c06f-06d4-4061-9a3e-f99e14e9f333","acronym":"","url":"https://clinicaltrials.gov/study/NCT00962845","created_at":"2021-05-06T10:52:31.702Z","updated_at":"2024-07-02T16:36:04.386Z","phase":"Phase 1","brief_title":"Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery","source_id_and_acronym":"NCT00962845","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BECN1","pipe":"","alterations":" ","tags":["BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 05/30/2013","primary_completion_date":" 05/30/2013","study_txt":" Completion: 05/30/2013","study_completion_date":" 05/30/2013","last_update_posted":"2022-09-07"},{"id":"b051e5c2-c3f3-4658-b8ef-4b4e0a0283e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00726596","created_at":"2021-05-06T10:52:28.670Z","updated_at":"2024-07-02T16:36:08.643Z","phase":"Phase 2","brief_title":"Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer","source_id_and_acronym":"NCT00726596","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BECN1","pipe":"","alterations":" ","tags":["BECN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2022-06-16"},{"id":"acaf9a0f-a467-43c2-8f34-dc61f9d4f9d3","acronym":"OMICC","url":"https://clinicaltrials.gov/study/NCT03661047","created_at":"2021-01-18T17:57:51.957Z","updated_at":"2024-07-02T16:36:20.624Z","phase":"Phase 2","brief_title":"OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer","source_id_and_acronym":"NCT03661047 - OMICC","lead_sponsor":"Massachusetts General Hospital","biomarkers":" PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • IL6 • LAG3 • TNFA • CTLA4 • HAVCR2 • TIGIT • IL10 • CCL2 • FOXP3 • ITGA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e icosapent ethyl"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2019","start_date":" 11/30/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2021-11-17"},{"id":"903268c5-41f0-41c5-a216-9dc491a7c313","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977470","created_at":"2021-01-18T03:48:48.527Z","updated_at":"2024-07-02T16:36:43.258Z","phase":"Phase 2","brief_title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","source_id_and_acronym":"NCT00977470","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • hydroxychloroquine"],"overall_status":"Unknown status","enrollment":" Enrollment 76","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-07-14"},{"id":"777cc931-d490-495e-8795-708c37a5d4f6","acronym":"PO1101944","url":"https://clinicaltrials.gov/study/NCT01128296","created_at":"2021-01-18T04:28:49.456Z","updated_at":"2024-07-02T16:37:00.034Z","phase":"Phase 1/2","brief_title":"Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT01128296 - PO1101944","lead_sponsor":"Amer Zureikat","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2019-05-01"},{"id":"691e5905-bfc6-4ce3-bbf6-6fcd2d44f850","acronym":"UPCI# 13-074","url":"https://clinicaltrials.gov/study/NCT01978184","created_at":"2021-01-18T09:00:34.196Z","updated_at":"2024-07-02T16:37:01.215Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine","source_id_and_acronym":"NCT01978184 - UPCI# 13-074","lead_sponsor":"Nathan Bahary, MD","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 02/06/2018","primary_completion_date":" 02/06/2018","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2019-03-27"}]